Royal Bank of Canada
SRNE

Royal Bank of Canada’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Royal Bank of Canada’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-200
Closed -$1K – 7288
2019
Q2 		$1K Buy
+200
New +$720 ﹤0.01% 6771

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

Royal Bank of Canada's SRNE Position: Q1 2023 in Review

Royal Bank of Canada sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 71,411 shares — an estimated $64K sold.

Royal Bank of Canada first reported a position in SRNE in Q2 2015 and held it in 27 quarters. The position peaked at $946K in Q4 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Royal Bank of Canada reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Royal Bank of Canada sold 71,411 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $64K.
  • Royal Bank of Canada first reported a position in Sorrento Therapeutics, Inc. in Q2 2015 and held it in 27 quarters.
  • Royal Bank of Canada's Sorrento Therapeutics, Inc. position peaked at $946K in Q4 2021.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Royal Bank of Canada's 13F filing for Q1 2023, filed 15 May 2023.